Atlas Venture Life Science Advisors, LLC

Portfolio Overview

Atlas Venture Life Science Advisors, LLC disclosed 6 positions worth $790.0M in its Form 13F-HR for Q1 2026, led by $KYMR (Kymera Therapeutics, Inc.) at 48.3% of the equity portfolio, followed by $DYN and $SION. During the quarter the fund opened 0 new positions and exited 2 and a full exit from $DAWN. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Atlas Venture Life Science Advisors, LLC’s Form 13F-HR filing with the SEC under CIK 1917529.

• 

  Kymera Therapeutics, Inc.

  $KYMR

  29.2#2,418

  Quality

  $381.3M4,578,008 sh
• 

  Dyne Therapeutics, Inc.

  $DYN

  —

  Quality

  $165.5M9,130,465 sh
• 

  Sionna Therapeutics, Inc.

  $SION

  —

  Quality

  $120.1M2,995,602 sh
• 

  Disc Medicine, Inc.

  $IRON

  —

  Quality

  $96.8M1,513,875 sh
• 

  Q32 Bio Inc.

  $QTTB

  23.1

  Quality

  $13.4M2,092,106 sh
• 

  Korro Bio, Inc.

  $KRRO

  5.8

  Quality

  $12.9M1,137,149 sh

Company	Quality	Value	Shares
Kymera Therapeutics, Inc.$KYMR	29.2#2,418	$381.3M	4,578,008
Dyne Therapeutics, Inc.$DYN	—	$165.5M	9,130,465
Sionna Therapeutics, Inc.$SION	—	$120.1M	2,995,602
Disc Medicine, Inc.$IRON	—	$96.8M	1,513,875
Q32 Bio Inc.$QTTB	23.1	$13.4M	2,092,106
Korro Bio, Inc.$KRRO	5.8	$12.9M	1,137,149

Showing top 6 of 6 holdings.

Full Holdings — Atlas Venture Life Science Advisors, LLC (Q1 2026)

All 6 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.

#	Ticker	Company	Value	Weight	QoQ	Quality
1	$KYMR	Kymera Therapeutics, Inc.	$381.3M	48.3%	-2%	29.2
2	$DYN	Dyne Therapeutics, Inc.	$165.5M	20.9%	+0%	—
3	$SION	Sionna Therapeutics, Inc.	$120.1M	15.2%	+0%	—
4	$IRON	Disc Medicine, Inc.	$96.8M	12.3%	+0%	—
5	$QTTB	Q32 Bio Inc.	$13.4M	1.7%	+0%	23.1
6	$KRRO	Korro Bio, Inc.	$12.9M	1.6%	+0%	5.8